Antibody therapy for Ebola

  • Qiu X
  • Kobinger G
N/ACitations
Citations of this article
19Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Ebola viruses can cause severe hemorrhagic fever in humans and nonhuman primates with fatality rates up to 90%, and are identified as biosafety level 4 pathogens and CDC Category A Agents of Bioterrorism. To date, there are no approved therapies and vaccines available to treat these infections. Antibody therapy was estimated to be an effective and powerful treatment strategy against infectious pathogens in the late 19th, early 20th centuries but has fallen short to meet expectations to widely combat infectious diseases. Passive immunization for Ebola virus was successful in 2012, after over 15 years of failed attempts leading to skepticism that the approach would ever be of potential benefit. Currently, monoclonal antibody (mAbs)-based therapies are the most efficient at reversing the progression of a lethal Ebola virus infection in nonhuman primates, which recapitulate the human disease with the highest similarity. Novel combinations of mAbs can even fully cure lethally infected animals after clinical sy...

Cite

CITATION STYLE

APA

Qiu, X., & Kobinger, G. P. (2014). Antibody therapy for Ebola. Human Vaccines & Immunotherapeutics, 10(4), 964–967. https://doi.org/10.4161/hv.27813

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free